Skip to main navigation Skip to search Skip to main content

The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression

  • Shih Chiang Huang
  • , Kwai Fong Ng
  • , Ta Sen Yeh
  • , Chi Tung Cheng
  • , Min Chi Chen
  • , Yi Chun Chao
  • , Huei Chieh Chuang
  • , Yu Jen Liu
  • , Tse Ching Chen*
  • *Corresponding author for this work
  • Chang Gung University

Research output: Contribution to journalJournal Article peer-review

52 Scopus citations

Abstract

Aims: In this study, we examine the clinicopathological and molecular features of gastric cancer (GC) with SMARCA4 alterations. Methods and results: We screened SMARCA4 alterations using immunohistochemistry on 1199 surgically resected GCs with information on Epstein–Barr virus (EBV), microsatellite instability (MSI) and other SWI/SNF subunits. SMARCA4, SMARCA2 and ARID1A mutations were investigated by targeted sequencing. The clinicopathological significance was determined by statistical analysis. Twenty-seven cases (2%) with altered SMARCA4 expression were identified, exhibiting completely lost (six), reduced (nine) or heterogeneous (12) patterns. Frequent concomitant alterations of other SWI/SNF subunits were noted with an unusual discordant spatial heterogeneity. In comparison with SMARCA4-retained GCs, SMARCA4-lost GCs were observed more frequently in the non-EBV/MSI subgroup (five of six) and reduced or heterogeneous SMARCA4 expression mainly occurred in EBV- or MSI-associated cases (six of nine and six of 12, respectively; P < 0.001). Histologically, SMARCA4-altered GC, irrespective of expression pattern, demonstrated divergent histomorphology, spanning tubular, poorly cohesive or mixed, neuroendocrine to solid and undifferentiated carcinoma, with a predilection to the latter two (P < 0.001). De-differentiation-like transition and rhabdoid features were noted in a minority of cases. For overall survival, altered SMARCA4 expression was an unfavourable prognostic factor in stage III, EBV-associated GC and non-EBV/MSI intestinal subtype (P ≤ 0.001). SMARCA4 or ARID1A mutations were detected mainly in SMARCA4-lost or reduced GC, respectively. Conclusions: SMARCA4-altered GCs are rare and have intratumoral heterogeneity, histomorphological diversity, conditional prognostic significance and various genetic drivers. SMARCA4-lost GC may represent a genuine SMARCA4-deficient neoplasm, but most SMARCA4-reduced/heterogeneous cases are secondary to ARID1A collapse or associated with different genotypes.

Original languageEnglish
Pages (from-to)250-261
Number of pages12
JournalHistopathology
Volume77
Issue number2
DOIs
StatePublished - 01 08 2020

Bibliographical note

Publisher Copyright:
© 2020 John Wiley & Sons Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Epstein–Barr virus
  • SMARCA4
  • SWI/SNF
  • gastric cancer
  • microsatellite instability

Fingerprint

Dive into the research topics of 'The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression'. Together they form a unique fingerprint.

Cite this